Low-dose intrathecal naloxone to enhance intrathecal morphine analgesia: A case report

Journal of Opioid Management

Volumn 4, Issue 4, 2008, Pages 251-254

  Hamann, Scott ^a   Sloan, Paul Alexander ^a   Witt, William ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Analgesia; Intrathecal morphine; Intrathecal naloxone; Spinal analgesics

Indexed keywords

MORPHINE; NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ARTICLE; CASE REPORT; DRUG COMBINATION; HUMAN; INFUSION; INTRACTABLE PAIN; INTRASPINAL DRUG ADMINISTRATION; LAMINECTOMY; LOW BACK PAIN; MALE; MIDDLE AGED; PAIN ASSESSMENT; QUALITY OF LIFE; TREATMENT OUTCOME;

ANALGESICS, OPIOID; DRUG THERAPY, COMBINATION; HUMANS; INFUSIONS, PARENTERAL; INJECTIONS, SPINAL; LAMINECTOMY; LOW BACK PAIN; MALE; MIDDLE AGED; MORPHINE; NALOXONE; NARCOTIC ANTAGONISTS; PAIN MEASUREMENT; PAIN, INTRACTABLE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 55249110431     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2008.0028     Document Type: Article

References (23)

1. Sloan PA, Kancharla A: Treatment of neuropathic pain with gabapentin. J Pain Palliative Care Pharm. 2003; 17: 89-94.
2. Sloan PA: Neuraxial pain relief for intractable cancer pain. Curr Pain Headache Rep. 2007; 11: 283-289.
3. Sloan PA, Hamann SR: Ultra low-dose opioid antagonists to enhance opioid analgesia. J Opioid Manage. 2006; 2: 295-304.
4. Hamann SR, Martin WR: Hyperalgesic and analgesic actions of morphine, U50-488, naltrexone and (-)-lobeline in the rat brain stem. Pharmacol Biochem Behav. 1994; 47: 197-201.
5. Lasagna L, Beecher HK: The analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man. J Pharmacol Exp Ther. 1954; 112: 356-363.
6. Wang HY, Friedman E, Olmstead MC, et al.: Ultra-low dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and GBY signalling. Neuroscience. 2005; 135: 247-261.
7. Hamann SR, Martin WR: Opioid and nicotinic analgesic and hyperalgesic loci in the rat brain stem. J Pharmacol Exp Ther. 1992; 261: 707-715.
8. Hamann SR, Wala EP, Rebel A, et al.: Selective antagonism of opioid excitatory receptor systems: a pilot clinical study demonstrating enhancement of morphine analgesia by low-dose naloxone in female patients undergoing elective abdominal laparotomy. Anesthesiology. 2004; 101: A-387.
9. Gan TJ, Ginsberg B, Glass PSA, et al.: Opioid-sparing effects of low-dose infusion of naloxone in patient-administered morphine sulphate. Anesthesiology. 1997; 87: 1075-1081.
10. Hamann SR, Sloan PA: Oral naltrexone to enhance analgesia in patients receiving continuous intrathecal morphine for chronic pain: a randomized, double-blind, prospective pilot study. J Opioid Manage. 2007; 3: 137-144.
11. Crain SM, Shen KF: Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain. 2000; 84: 121-131.
12. Shen KF, Crain SM: Antagonists at excitatory opioid receptors on sensory neurons in culture increase potency and specificity of opiate analgesics and attenuate development of tolerance/dependence. Brain Res. 1994; 636: 286-297.
13. Hamann SR, Malik H, Sloan JW, et al.: Interactions of "ultralow" doses of naltrexone and morphine in mature and young male and female rats. Receptor Channels. 2004; 10: 73-81.
14. Narita M, Imai S, Yajima Y, et al.: Possible involvement of mu1-opioid receptors in the fentanyl- or morphine-induced antinociception at supraspinal and spinal sites. Life Sci. 2002; 70: 2341-2354.
15. Lunzer MM, Yekkirala A, Hebbel RP, et al.: Naloxone acts as a potent analgesic in transgenic mouse models of sickle cell anemia. Proc Natl Acad Sci USA. 2007; 104: 6061-6065.
16. Wu HE, Sun HS, Cheng CW, et al.: D-Naloxone or L-naloxone reverses the attenuation of morphine antinociception induced by lipopolysaccharide in the mouse spinal cord via a non-opioid mechanism. Eur J Neurosci. 2006; 24: 2575-2580.
17. Do Ouro S, Esteban S, Sibirceva U, et al.: Safety and tolerability of high doses of intrathecal fentanyl for the treatment of chronic pain. J Opioid Manage. 2006; 2: 365-368.
18. Cruciani RA, Arbuck DM: Ultra-low dose oral naltrexone decreases side effects and potentiates the effect of methadone. J Pain Symptom Manage. 2003; 25: 491-494.
19. Tsai RY, Jang FL, Tai YH, et al.: Ultra-low-dose naloxone restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in PTX-treated rats. Neuropsychopharmacology. 2008 (in press).
20. Milne B, Jhamandas K: Naloxone: New therapeutic roles. Can Anaesth Soc J. 1984; 31: 272-278.
21. Fishman J, Hahn EF, Norton BI, et al.: Preparation and evaluation of a sustained naloxone delivery system in rats. Pharmacology. 1975; 13: 513-519.
22. Panchagnula R, Bokalial R, Sharma P, Khandavilli S: Transdermal delivery of naloxone: Skin permeation, pharmacokinetic, irritancy and stability studies. Int J Pharm. 2005; 293: 213-223.
23. Lenton S, Hargreaves K: A trial of naloxone for peer administration has merit, but will the lawyers let it happen? Drug Alcohol Rev. 2000; 19: 365-369.